Reblozyl Disease Interactions

Pharmacokinetic studies of luspatercept demonstrated no clinically significant differences in patients with mild to severe hepatic impairment and in patients with mild to moderate renal impairment. The effect of severe renal impairment on luspatercept pharmacokinetics is unknown. Care is recommended.

Thromboembolic events (TEE) have been reported in luspatercept-treated patients with beta-thalassemia. Patients with known risk factors for thromboembolism may be at increased risk of thromboembolic events. It is recommended to monitor patients for signs and symptoms of thromboembolic events and consider thromboprophylaxis in patients with beta-thalassemia at increased risk of TEE.

The use of luspatercept may cause hypertension. It is recommended to monitor blood pressure before each dose administration. New-onset hypertension or exacerbation of preexisting hypertension should be managed with anti-hypertensive drugs as clinically appropriate.